RNAi IPOs and Biotech Breakthroughs
Kilder
- Endpoints: ADARx prices $446.3M Nasdaq debut, continuing industry's IPO momentum
- Endpoints: Alnylam alumni lead RNAi biotech City Therapeutics to IPO filing
- Endpoints: Endpoints 11 2026 winner Azalea melds gene editing and CAR-T
- Businesswire: Endpoints News Announces the 2026 Winners of the Endpoints 11 Awards, showcasing biotech’s most exciting startups - Business Wire
- Endpoints: Biotech's most exciting startups of 2026: Meet this year's Endpoints 11 - Endpoints News
- Endpoints: Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split
- Labiotech: Theialife’s race to bring a childhood myopia treatment to market
- Finance: Theialife’s race to bring a childhood myopia treatment to market｜Beyond Biotech - finance.biggo.com
- Finance: Thomas Ruggia: The €100B Myopia Market Has No Drug, No Reimbursement, and a Fix - finance.biggo.com
- GEN: New CRISPR-Based Tool Enables Genome-Wide Mutagenesis of Bacteriophages
- Nature: Defining the essential genome of diverse phages with phage Tn-seq - Nature
- News-medical: New tool to mutate phages boosts the fight against superbugs - News-Medical
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.